34848-65-2

Basic information

• Product Name: 2-(2-acetyl-4-fluorophenoxy)acetic acid
• Synonyms: 2-(2-acetyl-4-fluorophenoxy)acetic acid
• CAS NO: 34848-65-2
• Molecular Formula: C₁₀H₉FO₄
• Molecular Weight: 212.1744632
• Mol File: 34848-65-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(2-acetyl-4-fluorophenoxy)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-acetyl-4-fluorophenoxy)acetic acid(34848-65-2)
• EPA Substance Registry System: 2-(2-acetyl-4-fluorophenoxy)acetic acid(34848-65-2)

Safety Data

• Hazardous Substances Data: 34848-65-2(Hazardous Substances Data)

Usage

General Description

2-(2-acetyl-4-fluorophenoxy)acetic acid is a chemical compound with a molecular formula C10H9FO4 and a molecular weight of 220.17 g/mol. It is a derivative of acetic acid and contains a fluorophenyl group and acetyl group. 2-(2-acetyl-4-fluorophenoxy)acetic acid is used as a building block in organic synthesis and as an intermediate in the production of pharmaceuticals and agrochemicals. It may also have potential applications in the development of new materials and functional molecules. Its chemical properties and reactivity make it a versatile compound for use in various fields of research and industry.

Upstream product

• 394-32-1 1-(5-fluoro-2-hydroxyphenyl)ethan-1-one 
• 371-41-5 4-Fluorophenol 
• 79-11-8 chloroacetic acid 
• 34849-57-5 (2-acetyl-4-fluorophenoxy)acetic acid ethyl ester 

Relevant articles and documents

Structure-activity relationships for a novel series of dopamine D2-like receptor ligands based on N-substituted 3-aryl-8-azabicyclo[3.2.1]octan-3-ol

Discovering dopamine D2-like receptor subtype-selective ligands has been a focus of significant investigation. The D2R-selective antagonist 3-[4-(4-chlorophenyl)-4-hydroxypiperidinyl]methylindole (1, L741,626; K i(D2R/D3R) = 11.2:163 nM) has previously provided a lead template for chemical modification. Herein, analogues have been synthesized where the piperidine was replaced by a tropane ring that reversed the selectivity seen in the parent compound, in human hD2LR- or hD3R-transfected HEK 293 cells (31, Ki(D2R/D3R) = 33.4: 15.5 nM). Further exploration of both N-substituted and aryl ring-substituted analogues resulted in the discovery of several high affinity D2R/D3R ligands with 3-benzofurylmethyl-substituents (e.g., 45, Ki(D2R/D3R) = 1.7:0.34 nM) that induced high affinity not achieved in similarly N-substituted piperidine analogues and significantly (470-fold) improved D3R binding affinity compared to the parent ligand 1. X-ray crystallographic data revealed a distinctive spatial arrangement of pharmacophoric elements in the piperidinol vs tropine analogues, providing clues for the diversity in SAR at the D2 and D3 receptor subtypes.

IMIDAZOPYRIDAZINE COMPOUNDS

The present invention relates to novel substituted imidazo[1,2-b] pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

Pyridazinone aldose reductase inhibitors

The present invention relates to novel pyridazinone compounds, pharmaceutical compositions comprising those compounds and to methods of using such compounds and compositions to inhibit aldose reductase, lower sorbitol levels and, thus, lower fructose levels, and/or treat or prevent diabetic complications such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic microangiopathy and diabetic macroangiopathy in mammals. This invention also relates to methods of affording cardioprotection to subjects not suffering from diabetes. This invention also relates to pharmaceutical compositions and kits comprising a combination of an aldose reductase inhibitor (ARI) of this invention and a sorbitol dehydrogenase inhibitor and to methods of using such compositions or kits to treat or prevent the above diabetic complications in mammals. This invention also relates to other combinations with the ARIs of this invention, including combinations with adendsine agonists; NHE-1 inhibitors; glycogen phosphorylase inhibitors; selective serotonin reuptake inhibitors; GABA agonists; antihypertensive agents; 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors; phosphodiesterase-5 inhibitors; and to glucose lowering agents.